Cure therapeutics and strategic prevention: raising the bar for mental health research
Cure therapeutics and strategic prevention: raising the bar for mental health research
复制标题
DOI：
10.1038/sj.mp.4001777
复制
发表时间：
2006-01-01
影响因子：
11
通讯作者：
Scolnick, EM
中科院分区：
文献类型：
--
作者：
Insel, TR;Scolnick, EM
在15至44岁的美国人中，精神障碍比任何其他类型的医学疾病都更容易导致残疾。自杀率高于凶杀、艾滋病和大多数癌症的年死亡率。与几乎所有传染性疾病和大多数非传染性疾病相反，几乎没有证据表明精神障碍的发病率和死亡率在过去几十年中发生了变化。包括精神病学研究人员在内的精神健康倡导者指出，污名化是精神疾病相对于其他医学疾病缺乏进展的原因之一。这篇评论考虑了研究界的期望和目标是如何导致这种相对缺乏进展的。与癌症和心脏病的研究人员寻求治疗和预防相反，学术界和工业界的生物精神病学家将目光投向了增量和可销售的进展，例如副作用较少的药物。本文主张的方法，可以导致治疗和预防精神分裂症和情绪障碍的战略。
Mental disorders cause more disability than any other class of medical illness in Americans between ages 15 and 44 years. The suicide rate is higher than the annual mortality from homicide, AIDS, and most forms of cancer. In contrast to nearly all communicable and most non-communicable diseases, there is little evidence that the morbidity and mortality from mental disorders have changed in the past several decades. Mental health advocates, including psychiatric researchers, have pointed to stigma as one of the reasons for the lack of progress with mental illnesses relative to other medical illnesses. This review considers how the expectations and goals of the research community have contributed to this relative lack of progress. In contrast to researchers in cancer and heart disease who have sought cures and preventions, biological psychiatrists in both academia and industry have set their sights on incremental and marketable advances, such as drugs with fewer adverse effects. This essay argues for approaches that can lead to cures and strategies for prevention of schizophrenia and mood disorders.